Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
Assistance Publique - Hôpitaux de Paris
2,250 participants
Nov 29, 2022
OBSERVATIONAL
Conditions
Summary
The objective of this work is to identify, in patients with autoimmune diseases, systemic vasculitis and autoinflammatory disease, cytokine and lymphocyte biomarkers of activity of these diseases to identify follow-up biomarkers, in order to personalize the follow-up and the treatments for each patient. Immunological data will be obtained from biological samples collected as part of the usual patient care pathway (Blood and tissues sampling) The study will take place in the Department of Internal Medicine and Clinical Immunology (DMIIC), that is certified as the National Reference Centre for Rare Systemic Autoimmune Diseases and the National Reference Centre for Inflammatory Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA). Its objective is to contribute to the advancement of fundamental knowledge in immunology, in particular to develop prognostic biomarkers of the activity of autoimmune diseases, systemic vasculitis and autoinflammatory diseases by using blood tests.
Eligibility
Inclusion Criteria11
- Patients of 18 years of age or older
- Patients with autoimmune systemic disease, systemic vasculitis or autoinflammatory disease, defined by the international criteria in force for each pathology, among the following:
- Connectivities: lupus, Sjögren syndrome, antiphospholipid syndrome, mixed connectivity and Sharp syndrome, scleroderma, myositis
- Vasculitis of large, small and medium vessels: giant cell arteritis, Takayasu arteritis, Behçet disease, ANCA vasculitis, cryoglobulinemic vasculitis, IgA vasculitis (rheumatoid purpura)
- Buerger's disease (obliterating thromboangitis)
- Granulomatosis and sarcoidosis
- Uveitis
- Monogenic and polygenic autoinflammatory diseases: family Mediterranean fever, TRAPS, CAPS, chronic atrophic polychondritis, pericarditis
- Recurrent fevers and unexplained inflammatory syndromes
- Inflammatory amyloidosis
- Patients affiliated to French social security
Exclusion Criteria5
- Vulnerable populations:
- Persons deprived of liberty by judicial or administrative decision;
- Persons receiving psychiatric care without their consent;
- Adult subject to a legal protection measure (guardianship, curatorship);
- Persons unable to give their consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
\- 56mL blood collected additionally to routine care
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05383339